4.0 Review

A Review of Strengths and Weaknesses of Different Imaging Options

期刊

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2013.02.001

关键词

Osteoarthritis; Imaging; Radiography; MR imaging; Ultrasonography; CT; PET

资金

  1. Genzyme
  2. Stryker
  3. Merck Serono
  4. Novartis
  5. Astra Zeneca
  6. General Electric Healthcare
  7. National Institutes of Health

向作者/读者索取更多资源

Slowing of radiographic joint space narrowing represents the only recommended imaging-based outcome measure to assess structural disease progression in osteoarthritis (OA) clinical trials. There are no effective disease-modifying OA drugs. The ability of magnetic resonance (MR) to image structures within the knee and to visualize cartilage morphology and composition gives MR imaging a critical role in understanding the natural history of the disease and in the search for therapies. In this article, the roles and limitations of conventional radiography and MR imaging, focusing on knee OA, and the use of other modalities in clinical practice and OA research are described.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据